AGENDA

1. Welcome and introduction

2. Apologies

3. Declarations of interest

4. Minutes of previous meeting

To protect commercial confidentiality the following appraisals will be held in private

5. Appraisal 1: Full Submission (PAS)
Ranibizumab (Lucentis®) for the treatment of visual impairment in adults due to choroidal neovascularisation not due to pathological myopia or wet age-related macular degeneration

6. Appraisal 2: Limited Submission (WPAS)
Icatibant acetate (Firazyr®) for the symptomatic treatment of acute attacks of hereditary angioedema in adolescents and children aged 2 years and older (with C1-esterase-inhibitor deficiency)

7. Appraisal 3: Full Submission (WPAS)
Selexipag (Uptravi®) for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class (FC) II–III, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type 5 (PDE-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies.

The meeting will now open to the public

8. Chairman's report (verbal update)

9. Common Ailments Service – Patient Information Leaflets

10. National Prescribing Indicators 2017-2018 Data to December 2017

Date of next meeting – Wednesday, 20th June in Cardiff